Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Time-varying belatacept exposure and its relationship to efficacy/safety responses in kidney-transplant recipients.

Zhou Z, Shen J, Hong Y, Kaul S, Pfister M, Roy A.

Clin Pharmacol Ther. 2012 Aug;92(2):251-7. doi: 10.1038/clpt.2012.84.

PMID:
22760001
2.

Belatacept: a new biologic and its role in kidney transplantation.

Su VC, Harrison J, Rogers C, Ensom MH.

Ann Pharmacother. 2012 Jan;46(1):57-67. doi: 10.1345/aph.1Q537. Review.

PMID:
22215686
3.

Belatacept in kidney transplantation.

Wojciechowski D, Vincenti F.

Curr Opin Organ Transplant. 2012 Dec;17(6):640-7. doi: 10.1097/MOT.0b013e32835a4c0d. Review.

PMID:
23044530
4.

Belatacept: a novel immunosuppressive agent for kidney transplant recipients.

Charpentier B.

Expert Rev Clin Immunol. 2012 Nov;8(8):719-28. doi: 10.1586/eci.12.79.

PMID:
23167683
5.

Belatacept: in adult kidney transplant recipients.

Garnock-Jones KP.

BioDrugs. 2012 Dec 1;26(6):413-24. doi: 10.2165/11208900-000000000-00000. Review.

PMID:
22928660
6.

Pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept in adult kidney transplant recipients.

Shen J, Townsend R, You X, Shen Y, Zhan P, Zhou Z, Geng D, Wu D, McGirr N, Soucek K, Proszynski E, Pursley J, Masson E.

Clin Drug Investig. 2014 Feb;34(2):117-26. doi: 10.1007/s40261-013-0153-2.

7.

Belatacept utilization recommendations: an expert position.

Grinyó JM, Budde K, Citterio F, Charpentier B.

Expert Opin Drug Saf. 2013 Jan;12(1):111-22. doi: 10.1517/14740338.2013.748747. Review.

PMID:
23206310
8.

Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation.

Martin ST, Tichy EM, Gabardi S.

Pharmacotherapy. 2011 Apr;31(4):394-407. doi: 10.1592/phco.31.4.394. Review.

PMID:
21449628
9.

A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, Massari P, Mondragon-Ramirez GA, Agarwal M, Di Russo G, Lin CS, Garg P, Larsen CP.

Am J Transplant. 2010 Mar;10(3):535-46. doi: 10.1111/j.1600-6143.2009.03005.x.

10.

Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients.

Ettenger RB, Grimm EM.

Am J Kidney Dis. 2001 Oct;38(4 Suppl 2):S22-8. Review.

PMID:
11583941
11.

A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study).

Durrbach A, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol J, Rial Mdel C, Florman S, Block A, Di Russo G, Xing J, Garg P, Grinyó J.

Am J Transplant. 2010 Mar;10(3):547-57. doi: 10.1111/j.1600-6143.2010.03016.x.

12.

Biological agents in kidney transplantation: belatacept is entering the field.

Wéclawiak H, Kamar N, Ould-Mohamed A, Cardeau-Desangles I, Rostaing L.

Expert Opin Biol Ther. 2010 Oct;10(10):1501-8. doi: 10.1517/14712598.2010.514901. Review.

PMID:
20726688
13.

Belatacept prophylaxis against organ rejection in adult kidney-transplant recipients.

Del Bello A, Marion O, Milongo D, Rostaing L, Kamar N.

Expert Rev Clin Pharmacol. 2016;9(2):215-27. doi: 10.1586/17512433.2016.1112736. Review.

PMID:
26691282
14.

Kidney transplant recipients treated with belatacept exhibit increased naïve and transitional B cells.

Leibler C, Matignon M, Pilon C, Montespan F, Bigot J, Lang P, Carosella ED, Cohen J, Rouas-Freiss N, Grimbert P, Menier C.

Am J Transplant. 2014 May;14(5):1173-82. doi: 10.1111/ajt.12721.

15.

Risk of posttransplant lymphoproliferative disorder associated with use of belatacept.

Martin ST, Powell JT, Patel M, Tsapepas D.

Am J Health Syst Pharm. 2013 Nov 15;70(22):1977-83. doi: 10.2146/ajhp120770. Review.

PMID:
24173007
16.

Costimulation blockade with belatacept in renal transplantation.

Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, Lang P, Grinyo J, Halloran PF, Solez K, Hagerty D, Levy E, Zhou W, Natarajan K, Charpentier B; Belatacept Study Group..

N Engl J Med. 2005 Aug 25;353(8):770-81.

17.

Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies.

Larsen CP, Grinyó J, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Breshahan B, Campistol JM, Florman S, Rial Mdel C, Kamar N, Block A, Di Russo G, Lin CS, Garg P, Charpentier B.

Transplantation. 2010 Dec 27;90(12):1528-35. doi: 10.1097/TP.0b013e3181ff87cd.

PMID:
21076381
18.

Profile of belatacept and its potential role in prevention of graft rejection following renal transplantation.

Gupta G, Womer KL.

Drug Des Devel Ther. 2010 Dec 1;4:375-82. doi: 10.2147/DDDT.S10432. Review.

19.

Rationale for using belatacept in combination with sirolimus.

Wéclawiak H, Kamar N, Ould-Mohamed A, Cardeau-Desangles I, Rostaing L.

Transplant Proc. 2010 Nov;42(9 Suppl):S29-31. doi: 10.1016/j.transproceed.2010.07.003. Review.

PMID:
21095447
20.

T-cell phenotype in protocol renal biopsy from transplant recipients treated with belatacept-mediated co-stimulatory blockade.

Grimbert P, Audard V, Diet C, Matignon M, Plonquet A, Mansour H, Desvaux D, Durrbach A, Cohen JL, Lang P.

Nephrol Dial Transplant. 2011 Mar;26(3):1087-93. doi: 10.1093/ndt/gfq453.

PMID:
20667993
Items per page

Supplemental Content

Support Center